You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 8,071,579

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,071,579

Title:	DNA damage repair inhibitors for the treatment of cancer
Abstract:	The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Inventor(s):	Ashworth; Alan (London, GB), Jackson; Stephen (Cambridge, GB), Martin; Niall (Cambridge, GB), Smith; Graeme (Cambridge, GB)
Assignee:	The Institute of Cancer Research: Royal Cancer Hospital (London, GB) Kudos Pharmaceuticals Limited (Cambridge, GB)
Application Number:	11/001,474
Patent Claims:	1. A method of treatment of cancer in an individual comprising; identifying a cancer cell obtained from the individual as deficient in homologous recombination (HR) dependent deoxyribonucleic acid (DNA) double strand break (DSB) repair relative to normal cells; and administering a poly(ADP-ribose)polymerase (PARP) inhibitor to said individual. 2. A method according to claim 1 wherein said cancer is identified as a HR dependent DNA DSB repair deficient cancer by determining the HR dependent DNA DSB repair activity of cancer cells from the individual. 3. A method according to claim 1 wherein the activity of the HR dependent DNA DSB repair pathway is determined in the cancer cells by measuring the formation of foci containing Rad51 in the nucleus in response to DNA damage or PARP inhibitors. 4. A method according to claim 1 wherein said cancer is identified as an HR dependent DSB repair deficient cancer by determining the presence in cancer cells from the individual of one or more mutations or polymorphisms in a nucleic acid sequence encoding a component of the HR dependent DNA DSB repair pathway. 5. A method according claim 1 wherein said cancer comprises one or more cancer cells having a reduced or abrogated ability to repair DNA DSB by HR relative to normal cells. 6. A method according to claim 5 wherein said cancer cells are deficient in breast cancer 1 (BRCA1) or breast cancer 2 (BRCA2). 7. A method according to claim 6 wherein said cancer cells are homozygous for a mutation in BRCA1 or BRCA2. 8. A method according to claim 6 wherein said cancer cells are heterozygous for a mutation in BRCA1 and/or BRCA2. 9. A method according to claim 1 wherein said PARP inhibitor is a phthalazin-1(2H)-one. 10. A method according to claim 2 wherein the HR dependent DNA DSB repair activity of cancer cells from the individual is determined relative to normal cells. 11. A method according to claim 2 where the cancer cell obtained from the individual is deficient in a HR dependent DNA DSB repair pathway relative to normal cells.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.